Neuvotion Announces Commercialization of Brain-Computer Interface and Brain-Body Interface Technologies – Related Clinical Study Published in Nature Medicine
Neuvotion is advancing AI-guided neuromodulation and brain–computer interface (BCI) technologies based on its founder’s groundbreaking research to create brain–body interfaces that restore movement, sensation, and independence for patients facing neurological injury and disease.
Neuvotion, Inc. is an early-stage medical device company developing an AI-guided neuromodulation platform to accelerate recovery after neurological events such as stroke and spinal cord injury. Its Brain-Body Interface (BBI) portfolio integrates wearable high-resolution muscle stimulation, spinal neuromodulation, and minimally invasive brain-computer interface (BCI) technologies to restore movement and sensation. By combining AI, intention-driven neurostimulation, and BCI technology, Neuvotion is translating newly published, peer-reviewed findings in Nature Medicine into commercially available solutions designed to help millions of people living with movement and sensory impairments regain function, independence, and quality of life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260727309885/en/ Neuvotion is developing AI-guided brain-body interface (BBI) technologies, defining a new category in medicine and revolutionizing neurorecovery.
